Artera, a Santa Barbara-based startup specializing in artificial intelligence (AI) for cancer testing and personalized care, recently raised $90 million in a funding round.
The funding will be used to support the distribution of Artera’s flagship prostate cancer testᅳArteraAI Prostate Testᅳin the United States and internationally, as well as for developing tests to aid therapy personalization in other types of cancer.
Investors in the round included Coatue, Johnson and Johnson Innovation, Koch Disruptive Technologies, Walden Catalyst Ventures, TIME Ventures, Breyer Capital, and The Factory, along with several angel investors such as Marc Benioff.
The ArteraAI Prostate Test predicts the benefits of therapy in localized prostate cancer.
The company has recently released data from six Phase III randomized trials, demonstrating the ability of its multimodal AI prognostic biomarker to enable personalized treatments.
Co-founder and CEO Andrej Esteva highlighted the potential impact of AI in the fight against prostate cancer, according to the American Cancer Society. By 2023, ArteraAI prostate tests will allow doctors and patients to use artificial intelligence to predict and adjust patient outcomes. Treatment decisions
More than 288,000 new cases of prostate cancer are expected to cause more than 3,000 deaths. By 2020, there will be more than 1 million new cases of prostate cancer and more than 375,000 related deaths worldwide. Founded in 2015, Artera has raised a total of $135 million in funding, according to data from Crunchbase. With the new funding, the company is poised to make significant progress in expanding AI-powered cancer detection and personalized care solutions.